 |
|
Colon Cancer Treatment (PDQ®)
[ patient ] [ health professional ]
Expert-reviewed information summary about the treatment of colon cancer.
Clinical Trials to Treat Colon Cancer
Check for colon cancer treatment trials from NCI's PDQ® Cancer Clinical Trials Registry now accepting patients. The list of clinical trials can be refined by location, stage of disease, drug, and other features.
Rectal Cancer Treatment (PDQ®)
[ patient ] [ health professional ]
Expert-reviewed information summary about the treatment of rectal cancer.
Clinical Trials to Treat Rectal Cancer
Check for rectal cancer treatment trials from NCI's PDQ® Cancer Clinical Trials Registry now accepting patients. The list of clinical trials can be refined by location, stage of disease, drug, and other features.
Bevacizumab Combined With Oxaliplatin-Based Chemotherapy Prolongs Survival for Previously Treated Patients With Advanced Colorectal Cancer
Preliminary results from a large, randomized clinical trial for patients with advanced colorectal cancer who had previously received treatment show that those who received bevacizumab (Avastin™) in combination with an oxaliplatin (Eloxatin™) regimen known as FOLFOX4 lived longer than patients who received FOLFOX4 alone.
FDA Approves Avastin as First Angiogenesis Inhibitor for Colorectal Cancer
Avastin (bevacizumab), is the first angiogenesis inhibitor approved to treat colorectal cancer that has spread to other parts of the body.
Bevacizumab (Avastin™) Improves Survival in Metastatic Colorectal Cancer
Patients with newly diagnosed metastatic colon cancer who received the therapeutic agent bevacizumab (Avastin™) along with the chemotherapy combination known as IFL had substantially longer overall survival times than patients who received IFL but with a placebo instead of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial.
FDA Approves Erbitux for Colorectal Cancer
Erbitux (cetuximab) is the first monoclonal antibody approved to treat patients with advanced colorectal cancer that has spread to other parts of the body.
Oxaliplatin-Based Regimen Prolongs Survival After Colorectal Cancer Surgery
The oxaliplatin-based chemotherapy combination known as FOLFOX significantly improved disease-free survival compared to 5-FU and leucovorin when used as adjuvant therapy (after surgery) in patients with stage II and stage III colorectal cancer.
Studies Suggest Exercise Improves Colorectal Cancer Outcomes
The results of two new prospective, observational studies offer compelling evidence to suggest that regular physical activity in the months following treatment may decrease the risk of cancer recurrence and death from colorectal cancer, according to the Aug. 1, 2006, issue of the Journal of Clinical Oncology.
Angiogenesis Inhibitors Therapy: Questions and Answers
A fact sheet that describes the process of eliminating the blood supply to tumors. Lists the cancers in which this approach is being tested. National Cancer Institute Fact Sheet 7.42
Biological Therapies for Cancer: Questions and Answers
A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies. National Cancer Institute Fact Sheet 7.2
Radiation Therapy for Cancer: Questions and Answers
A fact sheet that defines the different types of radiation therapy and discusses scientific advances that improve the effectiveness of this treatment. National Cancer Institute Fact Sheet 7.1
Targeted Cancer Therapies: Questions and Answers
This NCI fact sheet describes targeted cancer therapies, which are drugs that block the growth and spread of cancer by interfering with specific molecules involved in carcinogenesis (the process by which normal cells are transformed into cancer cells) and tumor growth. National Cancer Institute Fact Sheet 7.49
Metastatic Cancer: Questions and Answers
A fact sheet about metastasis, the spread of cancer to other parts of the body. Discusses the diagnosis and treatment of cancer that has spread. National Cancer Institute Fact Sheet 6.20
|
|
|
